Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Therapy Trends KOL Insight: Malignant Melanoma [2018]
    Learn More Therapy Trends KOL Insight: Malignant Melanoma [2018]
    What developments are on the horizon for malignant melanoma? The introduction of novel targeted systemic therapies has provided clinicians with valuable interventions for the treatment of malignant melanoma, however...
  • Therapy Trends KOL Insight: Prostate Cancer [2018]
    Learn More Therapy Trends KOL Insight: Prostate Cancer [2018]
    How will established and emerging agents reshape the prostate cancer treatment landscape? A plethora of novel therapies have been approved for prostate cancer over the past ten years, but what does the future hold? Key...
  • Colorectal Cancer: KOL Insight [2018]
    Learn More Colorectal Cancer: KOL Insight [2018]
    Are immunotherapies set to revolutionise the treatment of colorectal cancer? Available therapies for metastatic colorectal cancer (mCRC) prolong survival by nearly three years, but for most patients, treatment...
  • Non-Hodgkin’s Lymphoma: KOL Insight [2018]
    Learn More Non-Hodgkin’s Lymphoma: KOL Insight [2018]
    What impact will CAR-T therapies have on the NHL treatment landscape? The non-Hodgkin’s lymphoma (NHL) treatment armamentarium has been dominated by rituximab-based chemotherapy regimens for over a decade. Last...
  • Duchenne Muscular Dystrophy: KOL Insight [2018]
    Learn More Duchenne Muscular Dystrophy: KOL Insight [2018]
    How are gene therapies expected to revolutionise the treatment of Duchenne Muscular Dystrophy? Duchenne muscular dystrophy (DMD) is a devastating and fatal neuromuscular genetic disease with no known cure and few...
  • Diabetes Mellitus: Early Stage Outlook [2018]
    Learn More Diabetes Mellitus: Early Stage Outlook [2018]
    Are novel technologies set to revolutionise diabetes?  Diabetes is a chronic disease that requires lifelong management; however, rapid developments in innovative diabetes technologies (D-tech) have greatly improved...
  • Non-Small Cell Lung Cancer: KOL Insight [2018]
    Learn More Non-Small Cell Lung Cancer: KOL Insight [2018]
    What are the next key opportunities for growth of IOs in NSCLC? The growth of IO in NSCLC continues unabated. As Merck & Co.'s Keytruda becomes increasingly dominant in the first-line metastatic setting, will it be...
  • Chronic Lymphocytic Leukaemia: KOL Insight [2018]
    Learn More Chronic Lymphocytic Leukaemia: KOL Insight [2018]
    How will targeted therapy combinations transform the treatment of CLL? Chemoimmunotherapy regimens incorporating Rituxan/MabThera have traditionally been the cornerstone of CLL treatment. How is this expected to change?...
  • Atopic Dermatitis: KOL Insight [2018]
    Learn More Atopic Dermatitis: KOL Insight [2018]
    Will new pipeline therapies transform the treatment of atopic dermatitis? New pipeline agents look set to transform the treatment of moderate-to-severe atopic dermatitis. Dupixent (dupilumab; Regeneron/Sanofi) has...
  • Bladder Cancer: KOL Insight [2018]
    Learn More Bladder Cancer: KOL Insight [2018]
    How can immune checkpoint inhibitors differentiate themselves in the competitive Bladder cancer space? Five PD-1/PD-L1 immune checkpoint inhibitors are approved for bladder cancer, but how are these therapies faring on...
  • Psoriasis: KOL Insight [2018]
    Learn More Psoriasis: KOL Insight [2018]
    How will next-generation biologics change the psoriasis treatment landscape?  The treatment of psoriasis is evolving and the range of therapies is set to diversify with the approval and introduction of novel...
  • KOL Insight: Oncology Solid Tumour Review (2018 Q2)
    Learn More KOL Insight: Oncology Solid Tumour Review (2018 Q2)
    KOLs speak out on recent events in the solid tumour landscape With so much happening in the solid tumour treatment landscape it’s important to understand how things are likely to evolve. Based on the insights of...
  • Future Innovations in Oncology: Early Stage Outlook [2018]
    Learn More Future Innovations in Oncology: Early Stage Outlook [2018]
    How is the Oncology treatment landscape expected to evolve over the next 10 years? Oncology treatment has undergone a dramatic shift over the past 20 years with many drugs entering the space greatly improving survival...
  • Renal Cell Carcinoma: KOL Insight [2018]
    Learn More Renal Cell Carcinoma: KOL Insight [2018]
    RCC: A new era of IO-based combination therapy The recent FDA approval of BMS’ Opdivo/Yervoy has pioneered a new immuno-oncology (IO)-based combination approach to the first-line treatment of RCC. How do KOLs view...
  • Multiple Myeloma: KOL Insight [2018]
    Learn More Multiple Myeloma: KOL Insight [2018]
    How do the multitude of emerging combination regimens stack up in MM? The treatment of multiple myeloma (MM) is rapidly evolving and the range of combination therapies is set to diversify with triplet and quadruple...
  • Gastric Cancer: KOL Insight [2018]
    Learn More Gastric Cancer: KOL Insight [2018]
    All change in the gastric cancer treatment landscape? KOLs speak out… The treatment of gastric cancer is rapidly evolving and the range of therapies is set to diversify with the approval and introduction of novel...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved